Gilead Sciences, Inc. $GILD Shares Purchased by Parallel Advisors LLC

Parallel Advisors LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 78,474 shares of the biopharmaceutical company’s stock after purchasing an additional 4,004 shares during the quarter. Parallel Advisors LLC’s holdings in Gilead Sciences were worth $9,632,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $28,000. Financial Consulate Inc. grew its stake in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares in the last quarter. North Star Investment Management Corp. grew its stake in Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 86 shares in the last quarter. BOCHK Asset Management Ltd acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $31,000. Finally, Godfrey Financial Associates Inc. acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. Daiwa Securities Group decreased their target price on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Citigroup lifted their target price on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price for the company. Sanford C. Bernstein reiterated an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Finally, Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares in the company, valued at $22,907,973.57. This trade represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock valued at $9,047,570 over the last three months. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 0.1%

Shares of Gilead Sciences stock opened at $129.18 on Friday. The business’s fifty day moving average price is $134.56 and its two-hundred day moving average price is $134.34. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The company has a market capitalization of $160.39 billion, a P/E ratio of 17.60 and a beta of 0.31. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the company’s inflammation pipeline and adding gamgertamig, a potential first-in-class T cell engager for autoimmune diseases. This can support the stock by broadening long-term growth opportunities. Article Title
• Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis, including improved ALP normalization, which strengthens the case for a larger liver disease franchise and potential regulatory momentum. Article Title
• Positive Sentiment: Additional coverage highlighted favorable Livdelzi data and the company’s expanding liver and oncology footprint, which may reinforce confidence in Gilead’s growth pipeline. Article Title
• Neutral Sentiment: Coverage also noted that Gilead is drawing investor attention and being compared with other healthcare names, but these articles are more commentary than a direct new catalyst. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan. While routine, insider selling can still weigh on sentiment for some investors. Article Title

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.